Finance & Economy
-

Alkem Brings Affordable Semaglutide to India: Weekly Therapy at ₹450
Mumbai : Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of semaglutide injection in India under the brand names “Semasize”, Obesema” and “Hepaglide”. Semaglutide is administered as a…
-

IHCL Champions Responsible Hospitality with Paathya & Bharat EkSaath Walkathon
~ Raises funds for Taj Public Service Welfare Trust ~ Chennai: Indian Hotels Company (IHCL), India’s largest hospitality company, continues to advance its sustainability and social impact agenda through Paathya, its ESG+ framework. Marking its…
-

Pidilite Industries Limited Showcases Fevicol Professional Series at INDIAWOOD 2026 in Bengaluru
~ Showcased advanced woodworking adhesive solutions designed for superior performance, durability and sustainability~ Bengaluru : Pidilite Industries Limited, India’s leading manufacturer of adhesives, sealants and construction chemicals, showcased its flagship Fevicol Professional Series at INDIAWOOD…
-

Dhan announces launch of the all-new Trading Terminal – DEXT T3, designed especially for Super Traders in India
Bangalore: Dhan (www.dhan.co) – one of India’s fastest-growing stock trading & investing platform, has today announced the launch of its highly anticipated trading terminal – DEXT T3, the trading terminal that allows traders to build…
-

Glenmark Pharmaceuticals Launches GLIPIQⓇ (Semaglutide) In India
Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325 Bangalore, India : Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company, today announced the launch of GLIPIQⓇ (semaglutide) in…
-

Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India
Bangalore : Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as “Zydus”), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names – SEMAGLYNTM, MASHEMATM and ALTERMETM, upon patent expiry in…





